Kornimate/medical-research-clean huggingface dataset:
patients with chronic hepatitis b and low viremia not receiving antiviral therapy

Conditions: Hepatitis B, Chronic

Summary: this observational long-term follow-up study will evaluate demographic, clinical, histological, biochemical, and virological parameters of patients with chronic hepatitis b and low viremia who do not require antiviral therapy according to current guidelines. liver stiffness values as detected by fibroscan and arfi will also be collected if available. all data will be collected at yearly intervals (minimum). patients included in the study are followed for up to 10 years. the target sample size is \<1000.


Eligibility criteria:
inclusion criteria: * adult patient, age 18-79 * chronic hepatitis b * hbv-dna \< 100.000 iu/ml * alt ≤2 x uln * recent liver histology and/or fibroscan measurement * willingness to sign informed consent exclusion criteria: * current or past antiviral therapy for hepatitis b * chronic hepatitis b in immune tolerance phase (hbeag positive, high viral load) * co-infection with hiv, hcv * malignant disease * hcc or other liver tumor
respiratory muscle training in acquired brain injury patients.

Conditions: Respiratory Disease; Muscle Weakness; Acquired Brain Injury; Older People--Abuse of; Physical Inactivity

Summary: background: respiratory health problems are one of the main causes of morbidity and mortality in adult people with acquired brain injury (abi). the influence of respiratory muscle training has not yet been studied in this population group. the objective of the study was to evaluate and compare the efficacy of two protocols with respiratory muscle training, inspiratory muscle training vs expiratory muscle training, to improve respiratory strength and pulmonary function in adults with cp. methods: the study is a controlled, randomised, double-blind trial and with allocation concealment. 26 abi patients will be recruited and randomly distributed in the inspiratory muscle training group (imt) and the expiratory muscle training group (emt). over an 8-week period an imt or emt protocol was followed 5 days/week, 5 series of 1-minute with 1-minute rest between them. imt trained with a load of 50% of the maximum inspiratory pressure (mip) and emt with 50% of the maximum expiratory pressure (mep). respiratory strength and pulmonary function were evaluated.


Eligibility criteria:
inclusion criteria: * belong to asdace. * sign the informed consent. exclusion criteria: the presence of a respiratory disease in the previous month, inability to understand assessment tests or intervention or hemodynamic alterations (heart rate \> 150 beats per minute (bpm), systolic blood pressure \> 140 millimeters mercury (mmhg) or diastolic blood pressure \> 90 mmhg).
spiritual care in improving quality of life of patients, caregivers, and hospital staff

Conditions: Malignant Neoplasm

Summary: this clinical trial studies spiritual care in improving quality of life of patients, caregivers, and hospital staff. spiritual care may help understand the impact cancer and its treatment has on patients, caregivers and hospital staff.

objectives: i. to improve the quality of spiritual care provided by palliative care teams. ii. to measure the effectiveness of integrating spiritual care recommendations in palliative care at city of hope (coh) and the impact it has on cancer patients, families, and hospital staff. outline: the expanded psychosocial/spiritual assessment administered by social workers includes a spiritual history and a spiritual needs screening. social worker knowledge and competence is surveyed at baseline, immediately after the course, and after a bedside chaplain-mentoring process. inpatient cancer patients' and their caregivers' perceptions about spiritual care is surveyed at baseline prior to the social work curriculum and after the course has been completed and the new psychosocial/spiritual assessment has been implemented. data collected from patients, family members, and staff includes number of unduplicated palliative care patients screened for spiritual concerns, spiritual history, number and type of spiritual issues, number of referrals to the chaplain, number seen by the chaplain, number of unduplicated palliative care patients with documented spiritual care plan, number of staff development sessions offered and topics, attendance per topic, advance directives, and referrals to hospice.

Eligibility criteria:
inclusion criteria: * admitted during the study quarter * admitted \>= 5 days * english speaking * alert and able to answer questions exclusion criteria: * non-cancer diagnosis * previously accrued to study
effects of a weight loss intervention in college-age women

Conditions: Weight Loss

Summary: determine the effects of an 8-week weight loss intervention.

the purpose of this study is three-fold: 1) determine whether an 8-week, patient-centered, weight loss intervention can be successfully implemented in overweight, college-age females for promotion of weight loss and prevention of weight regain at 8-weeks, three months, and six months follow-up; 2) determine the effects of the intervention on established markers of calorie restriction, energy expenditure and body composition; 3) determine the effects of a liquid meal on physiological and subjective markers of hunger and satiety from pre- to post- 8wk intervention in the intervention group vs control group.

Eligibility criteria:
inclusion criteria: * females age 18-25years * body mass index 25.0 to 29.9 kg/m2 (overweight) * agree to receive frequent contacts from investigators and communicate with program staff for up to 6 months * willing to measure blood glucose via finger prick test three to eight times per day for two weeks * able to give written informed consent * able to comply with study procedures exclusion criteria: * unable or unwilling to give informed consent * travel plans that do not permit participation * pregnant or planning on becoming pregnant during the 6 months of participation in the study * weight loss or gain exceeding 5% of body weight in the past 3 months * current participation in a weight loss program * diagnosis of mental disorder or chronic disease * history of eating disorder such as anorexia nervosa, bulimia nervosa, or binge eating disorder (unless approved by program staff) * history of surgery or procedure that could affect swallowing or digestion * any person who is on a medically prescribed diet * any current supplement use other than a daily multivitamin * any current metabolic medication use other than birth control * any bleeding disorders or blood clotting problems * anyone who has donated blood or plasma in the last 20 days * any tobacco or illicit drug users * anyone who has allergies to any of the components of the liquid meal
cohort study of healthcare workers receiving imvanex®

Conditions: Monkeypox

Summary: during an outbreak of monkeypox in the uk in 2018, a third generation smallpox vaccine, imvanex, was used for the first time to immunise healthcare workers who had been, or were expected to be, in contact with cases of monkeypox. this study will examine the antibody responses in these healthcare workers compared to control groups, to provide evidence that the vaccine can produce a response consistent with protection when used in this context.

this study intends to describe antibody responses to a third generation smallpox vaccine, imvanex® (mva-bn, bavarian nordic gmbh; also known as imvamune®), in cohorts of individuals who received the vaccine for pre-exposure or post-exposure prophylaxis against monkeypox during a monkeypox outbreak in the uk. in addition to quantifying anti-vaccinia virus antibody responses to vaccine, the study intends to demonstrate that vaccine-induced antibodies neutralise the specific monkeypox viruses involved in the uk outbreak, and also reference monkeypox viruses. the use of imvanex® during the uk outbreak represents the first ever use of imvanex® as a public health intervention for a monkeypox outbreak, and this study will provide an opportunity to quantify and characterise antibody responses to imvanex® administered in a non-trial setting.

Eligibility criteria:
inclusion criteria for pre-exposure prophylaxis cases: * a high consequence infectious disease (hcid) centre healthcare worker involved in the care of a confirmed monkeypox case * and the individual has received imvanex® during the outbreak period * and no known unprotected exposure to a monkeypox case (i.e. pre-exposure indication for vaccination) inclusion criteria for post-exposure prophylaxis cases: * a healthcare worker * and the individual has received imvanex® during the outbreak period * and unprotected exposure to a monkeypox case is believed to have occurred (i.e. post-exposure indication for vaccination) inclusion criteria for control group 1 (unvaccinated hcid staff caring for confirmed cases): * a high consequence infectious disease (hcid) unit healthcare worker involved in the care of a confirmed monkeypox case * and the individual has not received imvanex® during the outbreak period * and no known unprotected exposure to a monkeypox case inclusion criteria for control group 2 (general healthcare workers): * a healthcare worker not involved in the care of a confirmed monkeypox case * and the individual has not received imvanex® during the outbreak period * and no known unprotected exposure to a monkeypox case exclusion criteria for all participants: * refusal by participant * age less than 18 years

Keywords: immunisation modified vaccinia ankara imvanex imvamune vaccine
efficacy of an ocular bandage contact lens for the treatment of dry eye after cataract surgery

Conditions: Cataract; Dry Eye

Summary: to study the efficacy of an ocular bandage contact lens for the treatment of dry eye after cataract surgery


Eligibility criteria:
inclusion criteria: 1. age-related cataract 2. dry eye disease exclusion criteria: 1. a history of surgery and other ocular diseases 2. contact lens use 3. ocular therapies such as 0.05% cyclosporine a or steroids in the last 3 months. had 4.any systemic diseases such as heart diseases, diabetes and psychosis.
neural correlates of ptsd prevention with mindfulness based stress reduction (mbsr) in iraqi veterans

Conditions: Stress Disorders, Posttraumatic; PTSD

Summary: the purpose of this study is to compare mindfulness based stress reduction to a supportive therapy control group.


Eligibility criteria:
inclusion criteria: * ptsd related to oef/oif service exclusion criteria: * history of brain injury
a pilot study of opc-8212 (vesnarinone) in persons with aids-related kaposi's sarcoma

Conditions: Sarcoma, Kaposi; HIV Infections

Summary: to examine the safety and efficacy of two doses of vesnarinone in patients with aids-related kaposi's sarcoma.

twenty-eight patients (14 per cohort) receive daily vesnarinone at one of two doses. at least seven patients at the lower dose must have completed 2 weeks of therapy before subsequent patients are entered at the higher dose. patients who successfully complete 16 weeks of treatment may receive maintenance therapy for the duration of the study (approximately 12-18 months).

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * chemoprophylaxis for pneumocystis carinii, candida, and mycobacteria. * acyclovir as acute treatment for herpes outbreaks. concurrent treatment: allowed: * limited electron-beam radiation therapy to non-marker lesions for treatment of kaposi's sarcoma. patients must have: * documented hiv infection. * kaposi's sarcoma. * no current constitutional signs of hiv disease or aids-defining conditions other than kaposi's sarcoma. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * active malignancy other than kaposi's sarcoma, cutaneous basal cell carcinoma, or in situ carcinoma of the cervix. * current significant cardiac disease or anomaly (including prolonged qtc on ekg). * abnormal cardio-thoracic ratio on chest x-ray. concurrent medication: excluded: * antiretroviral agents, including ddi, ddc, azt, and d4t. * immunosuppressive agents. * investigational hiv drugs/therapies including vaccines (except those on treatment ind for approved indications). * other anti-kaposi's sarcoma/hiv drugs. * corticosteroids (other than topical). * biologic response modifiers. * megestrol acetate. * agents known to cause neutropenia. * trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg sulfamethoxazole thrice weekly. * cytotoxic chemotherapy. concurrent treatment: excluded: * radiation therapy including electron beam irradiation (other than limited electron-beam radiation to non-marker lesions for treatment of kaposi's sarcoma). patients with the following prior conditions are excluded: * prior history of significant cardiac disease or anomaly. * history of agranulocytosis or severe grade 3 drug-induced neutropenia or documented abnormalities in granulocyte function. prior medication: excluded: * azt within 14 days prior to study entry. * acyclovir as prophylaxis for herpes within 48 hours prior to study entry. excluded within 30 days prior to study entry: * interferon. * biologic response modifiers. * cytotoxic chemotherapy. prior treatment: excluded within 30 days prior to study entry: * blood or cellular blood product. active illicit drug abuse (specifically cocaine, amyl nitrate, heroin, or other cardioactive agents).

Keywords: sarcoma, kaposi acquired immunodeficiency syndrome antiviral agents vesnarinone
parenting mindfully study

Conditions: Substance Abuse; Risk Behaviors

Summary: the goal of study is to develop and test a parenting-focused version of mindfulness intervention ("parenting mindfully") to reduce parent stress and prevent adolescent substance use and hiv risk behaviors (e.g., risky sex). the investigators hypothesize that parenting mindfully (pm) will decrease prevent adolescent substance use and hiv risk behaviors and intentions. secondarily, pm will improve parenting, and decrease adolescent stress responses.


Eligibility criteria:
inclusion criteria: 1. family with a child between 12-16 years; 2. high parenting stress (mean score of \>=3 on 2 questions adapted from the perceived stress scale and the parenting stress index). exclusion criteria: 1. diagnosis of mental retardation, autism or other pervasive developmental disorder for adolescent; 2. current serious psychiatric or medical disorder (including current substance dependence) requiring immediate treatment for adolescent or parent- we will include those that are in treatment; 3. medical condition that would preclude participation in gentle yoga (for parents) 4. inadequate english proficiency to complete questionnaires for youth or parents.

Keywords: adolescence substance abuse mindfulness
measurement and evaluation of total lung capacity (tlc) in the field of pulmonary functional testing (pft)

Conditions: TLC in Patients With and Without Respiratory System Disease

Summary: a comparative study to test the efficacy of a novel device - the miniboxpft, in measuring tlc (total lung capacity) compared to tlc measured by standard body plethysmography using the zan 500. the study will be conducted as a prospective two-arm, open, randomized comparative study.

this study is a prospective, multi-centered, randomized, comparative study designed to demonstrate substantially equivalence performance of the proposed device, the pulmone miniboxpft, to its predicate device, the zan500, for the measurement of total lung capacity (tlc).

Eligibility criteria:
inclusion criteria: 1. subject is at least 18 years of age. 2. subject is cooperative and capable of following instructions. 3. healthy subjects: 1. never smokers. 2. no known history of respiratory, cardiovascular, hepatic, renal or metabolic disease. 3. bmi \< 35. 4. no persisting respiratory symptoms during the last 12 months. (e.g., dyspnea, chronic cough, wheezing or phlegm). 5. no history suggesting upper respiratory infection during the three weeks prior to testing. 4. patients with known disease affecting the respiratory system, with previous documentation of obstructive, restrictive, or mixed obstructive plus restrictive ventilatory abnormality. exclusion criteria: 1. subjects who are unable to satisfactorily perform routine, full lung function testing(due to non-compliance or claustrophobia). 2. subjects unable or unwilling to give informed consent. 3. subjects who have performed any significant physical activity during 1 hour prior to the study. 4. patients with a tracheostomy. 5. pregnant women.

Keywords: total lung capacity
exploration of patient self-medication practices during and after cancer in france

Conditions: Cancer; Self-medication

Summary: the purpose of this study is to assess the patient self-medication practices during and after cancer in france, using an online questionnaire

patients will be contacted by email from patient's associations. patients will be informed of the objectives of the study and will be free to answer or not to the online questionnaire.

Eligibility criteria:
inclusion criteria: * past or active cancer exclusion criteria: * speaking french * not living in france

Keywords: cancer self-medication quality of life
pediatric acute kidney injury (aki) retrospective, real-time and repository research

Conditions: Acute Kidney Injury; Renal Injury; Kidney Disease

Summary: this proposal will incorporate statistical models developed by the investigators to predict risk for acute kidney injury into our electronic medical record system, enabling an alert to notify providers of the risk status. pediatric inpatients will be randomly assigned to be in the intervention group, for whom the notification will be implemented, or in the control group, who will receive usual care (no notification). the investigators believe the notification will increase appropriate screening for acute kidney injury and reduce the severity of acute kidney injury in the intervention group.

this proposal will incorporate a logistic regression models developed by the investigators to predict risk for acute kidney injury in pediatric intensive care unit and pediatric ward patients into the electronic medical record system, enabling personalized decision support. real-time surveillance using the risk prediction models will identify pediatric inpatients at increased risk for acute kidney injury. when patients exceed the threshold risk for acute kidney injury, the electronic medical record system will notify providers. patients will be randomly assigned to be in the intervention group, for whom the notification will be implemented, or in the control group, for whom the notification will not display. the risk notification will be assessed for its impact on outcomes including rates of screening for acute kidney injury and the severity of acute kidney injury.

Eligibility criteria:
inclusion criteria: * all admissions to the pediatric intensive care unit or pediatric wards at the monroe carell junior children's hospital at vanderbilt exclusion criteria: * prior diagnosis of chronic renal disease, including dialysis and transplant * admission to the neonatal intensive care unit during the current admission

Keywords: pediatrics
metformin in intracytoplasmic sperm injection cycles

Conditions: Intracytoplasmatic Sperm Injection

Summary: the relationship between serum progesterone level on the day of human chorionic gonadotropin administration and outcome of in vitro fertilization /intracytoplasmic sperm injection and embryo transfer has been controversial for several decades. some studies presented data against the negative effect of premature luteinization and reported that elevated serum progesterone had no adverse effect on pregnancy rates in fresh embryo-transfer cycles within different ovarian responses. however, most studies have evaluated the association between serum progesterone level and clinical outcome in fresh in vitro fertilization /intracytoplasmic sperm injection cycles and advocated that serum progesterone elevation on the day of human chorionic gonadotropin administration may adversely affect the clinical outcome by jeopardizing endometrial receptivity. in addition, the underlying mechanism through which premature luteinization influences clinical outcomes is elusive. some proposed that premature luteinization cause impairment of the endometrial receptivity, which may indicate a change in the implantation window, is more likely to be affected than the oocyte.whereas some documented that the compromised quality of oocytes might also be a cause. the cut-off point of premature luteinization is not well established until now. premature luteinization has been variously defined based on serum p levels, with thresholds of 0.9-1.5 ng/ml being used. previous studies have shown that metformin inhibits the first steps of steroidogenesis dose-dependently reducing granulosa cells progesterone output. moreover, other authors have recently reported that low dose metformin could improve in vitro fertilization outcome in non poly-cystic ovarian syndrome repeaters. so, considering the safety of this drug before pregnancy, metformin can be given to consenting patients from first ultrasound monitoring until ovulation triggering.


Eligibility criteria:
inclusion criteria: * first or second trial icsi cycle. * age: 20 -38 years * bmi: patients with bmi ≥ 30 kg/m2 were advised to lose weight for 6 months through lifestyle modifications. * amh ≥1 ng/ml * basal fsh \< 10 iu/ml. * normal uterine cavity evidenced by hsg or office hysteroscopy * normal levels of prolactin and tsh before starting cos cycle exclusion criteria: * patients with recurrent two or more failed intra-cytoplasmic sperm injection cycles. * uterine anomalies or synechiae. * severe male factor infertility * patients known to have diabetes, renal, liver disease, alcoholism, or drug abuse were excluded * patients who were on metformin treatment were asked to have a one month washout period before study participation. * poor responders
anti-inflammatory effects of pioglitazone

Conditions: Impaired Glucose Tolerance; Type 2 Diabetes Mellitus; Atherosclerosis

Summary: there is increasing evidence that inflammation plays a role in progression and destabilization of atherosclerotic plaque. fdg-pet can visualize activated metabolic activity of inflammatory cells. it is possible that fdg-pet can detect atherosclerotic plaque inflammation and that fdg-pet can monitor the effect of pioglitazone on plaque inflammation.

atherosclerotic patients with impaired glucose tolerance and type 2 diabetes will undergo the fdg-pet/ct imaging at baseline and again following 4 months after treatment. patients who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone or 4 mg/day glimepiride. physical examinations will be done at baseline, 4 months, and 12 months. during study, subjects will have body weight, and vital signs (hr, bp, etc) assessed as well as waist circumference. laboratory assessments will be done at each baseline, 4 month.

Eligibility criteria:
inclusion criteria: * subjects between the ages of 35 and 85 years * subjects with impaired glucose tolerance and type 2 diabetes, who had atherosclerosis detected by carotid ultrasound and/or ct * subjects who had vascular fdg uptake by fdg-pet exclusion criteria: * subjects with insulin treatment * subjects with uncontrolled diabetes, hypertension, symptomatic coronary artery disease, symptomatic cerebrovascular disease * subjects taking more than three antidiabetic medications * subjects taking anti-platelet, statins, antidiabetic agents, thiazolidinediones (tzds) within 8 weeks prior to randomization * subjects with cardiac failure (new york heart association class \> iii) or left ventricular dysfunction (lvef \< 40%) * subjects with systemic disorders such as active inflammatory, liver, renal, hematopoietic, and malignant disease